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Osteochondrosis (OC) is a developmental disease in horses with a significant impact on the horse’s 
welfare and performance. The early disturbance of enchondral ossification progresses to inflam-
matory and healing process in older horses. Metabolic pathway analysis showed an obvious dy-
sregulation of several signaling pathways related to cartilage formation and cartilage repair such 
as Wnt/β-catenin, Indian hedgehog and TGF-β signaling pathways. Other regulated genes ap-
peared to be involved in high carbohydrate diet, abnormal insulin metabolism or inflammation. 
Sclerostin is an osteocyte-secreted soluble antagonist of the Wnt/β-catenin signaling pathway. It is 
crucial for osteoblast development and activity and is increased in naturally occurring lesions of 
equine osteochondrosis. The aim of this study is to compare the circulating sclerostin levels be-
tween OC-affected (n = 20) and healthy horses (n = 19). A significant linear regression between 
plasma sclerostin and age is observed especially in the healthy young horses. The mean plasma 
sclerostin concentration is significantly higher in young horses suffering from osteochondrosis 
compared to the control horses. These results reinforce the possible role of the Wnt/β-catenin 
signaling pathway in the OC pathogeny. The inhibition of this essential pathway could disturb the 
osteo-chondral differentiation. More studies are currently needed to define the eventual clinic in-
terest of plasma sclerostin as future biomarker in bone and cartilage diseases. 
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1. Introduction 
Osteochondrosis (OC) is a developmental disease of growing horses. It is defined as a disturbance in the process 
of endochondral ossification [1] which can lead to the formation of detached fragments (osteochondrosis disse-
cans (OCD)), fissures, or subchondral bone cysts at the epiphyseal growth cartilage [1] [2]. OCD is a frequent 
cause of pain, lameness and reduced performance in young athletic horses [3] [4]. The disease appears to be 
multifactorial in origin, including skeletal growth rates, nutrition, endocrinological factors, exercise, biome-
chanics, and genetic effects [5]. 
In a previous study, we analyzed the transcript profile of leukocytes from horses affected with OC using the 
high throughput sequencing method digital gene expression analysis [6]. Metabolic pathway analysis showed an 
obvious deregulation of several signaling pathways related to cartilage formation and cartilage repair such as 
Wnt/β-catenin, Indian hedgehog- and TGF-β signaling pathways. Other regulated genes may play a role in high 
carbohydrate diet, abnormal insulin metabolism or inflammation [6]. Power and others [7] demonstrated that 
sclerostin protein is increased in naturally occurring lesions of equine osteochondrosis.  
Sclerostin is a small protein specifically expressed by osteocytes which antagonizes canonical Wnt/β-catenin 
signaling by binding to Wnt co-receptors, low-density lipoprotein receptor-related protein 4, 5 and 6 [8] (Figure 1). 
Sclerostin coded by the SOST gene in osteocytes. Sclerostin is mainly produced in respond to mechanical stress 
applied to the skeleton. It appears to play an important role in the regulation of bone remodeling [9]. Recent stu-
dies have shown that the SOST gene is also expressed by articular chondrocytes and that modulation of its activ-
ity may have effects on articular cartilage and subchondral bone [10].  
In humans, serum sclerostin levels are gender dependent and increase with age as well as in several patholo-
gies such as diabetes, obesity and osteoporosis [11]-[13]. In cases of juvenile idiopathic arthritis (JIA), soluble 
antagonists of the canonical Wnt/β-catenin signaling were measured in serum and subsequently induced inhibi-
tion of osteoblast proliferation, maturation, and progenitor differentiation. A significant correlation between the 
sclerostin serum concentration and the number of tender and swollen joints supports the hypothesis that chon-
drocytes and cells of the subchondral bone may contribute to circulating sclerostin in JIA [14]. 
The aim of the present study is to demonstrate the implication of the Wnt/β-catenin signaling pathway by 
measuring in young horses suffering from osteochondrosis, the concentration of circulating sclerostin and to 
compare these values to a group of healthy horses without any suspect radiologic signs of osteochondrosis.  
2. Materials & Methods 
2.1. Population 
Thirty-nine young Belgian Warm blood horses, with a mean age of 268 (±63.55) days, were selected for this 
study which followed a “case control study” model. Selection was made between 125 examined horses in 2014 
on the base of the uncountable results of the radiographies. The foals were presented at the European Center of 
the horse (Vielsalm, Belgium) by the breeders in the context of the orthopedic diseases screening program pro-
moted by the Wallonia Region. All the foals were weaned and fed a diet based on hay or haylage and concen-
trates. The OC affected group was composed of 6 females and 14 males. The control group was composed of 9 
females and 10 males. Although veterinary examinations were performed routinely, the ethics committee of the 
University of Liege has agreed to the study protocol. 
2.2. Radiographic Exam 
All horses were sedated for the radiographic examination using detomidine (0.01 mg/kg IV) alone or combined 
with butorphanol (0.02 mg/kg IV). The following views were taken: lateromedial views of the 4 fetlocks, late-
romedial and plantarolateral-dorsomedial oblique views of the hocks and a lateromedial view of the stifles. Ex-
tra views were taken when necessary. Horses were diagnosed on the basis of characteristic lesions of abnormal 
endochondral ossification located in the metacarpo and metarso-phalangeal, tibiotarsal, and femoro-patellar 
joints [15]. The foals presenting one lesion in the fetlock joint such as fragmentation and irregularity observed 
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on the dorsal aspect of the sagittal ridge and the condyles of the metacarpus or metatarsus or dorsal, palmar or 
plantar fragmentations at the margin of the proximal phalanx were not included in this study. Concerning the 
stifle joint, variably sized irregularity or flattening of the lateral trochlear ridge of the femur with sometimes par-
tial calcification of the tissue within the defect were considered as OC-lesions (Figure 2(a)). Concerning the 
hock, OC-lesions were identified as fragments still in place (intermediate ridge) (Figure 2(b)) or surface irregu-
larities of the trochlear ridge(s) or malleolus. Horses with osteoarthrosis and other radiological abnormalities 
were also excluded of this study.  
The OC-affected group included 20 horses and 19 horses without any evidence of OC lesions were analyzed 
as control groups. At the moment of the radiographic exams, blood samples were collected from each horse on 
EDTA or dry tubes. Plasma and serum were frozen at −20˚C for later analysis. 
2.3. Sclerostin Assay 
Serum sclerostin concentrations were determined by a sandwich ELISA kit designed and validated specifically 
 
 
Figure 1. Modulation of the Wnt B-catenin pathway by sclerostin (modified from M. Lewiecki, 2011, discovery medicine) 
The binding of Wnt proteins to the LRP5/6-Frizzled co-receptor on the cell membrane leads to stabilization of intracellular 
β-catenin and regulation of gene transcription that promotes ossification. Sclerostin by binding to LRP5/6 antagonizes Wnt 
signaling and inhibits enchondral ossification.                                                                 
 
 
(a)                                                (b) 
Figure 2. OC lesion in the lateral ridge of the femoral trochlea (a) and OC lesion of the intermediate ridge of the tibial 
trochleaas examples of the lesions found during the radiographic exams.                                            
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for equine samples (Horse Sclerostin (SOST) ELISA Kit, MyBioSource, BiopTis). Sclerostin standards ranging 
from 31.2 to 1000 pg/ml andundiluted serum were added (50 µl) into the wells of a microplate then 100 μl of 
HRP-conjugate reagent was added to each well. The microplate was incubated for 60 minutes at 37˚C. After in-
cubation, the microplate was washed 4 times with the wash solution of the kit and 100 µl of the TMB-pero- xi-
dase substrate (mix of chromogen solutions A and B) was added to reveal the peroxidase activity of the HRP 
conjugate. The plate was incubated for 15 minutes at 37˚C then 50 µl of the acidic stop solution was added. The 
absorbance of the yellow color was read at 450 nm with the Multiscan Ascent plate reader. Each sample was as-
sayed twice and the mean value was calculated. According to the firm, the sensitivity of the kit is 5.0 pg/ml. 
2.4. Statistical Analysis 
Equality of variances was assessed by Levene’s test. Linear regressions were calculated between the values of 
sclerostin and age in all horses and then in each group. A global linear model was used to compare the mean 
values of plasma concentrations of sclerostin (variable) between the OC-affected group and the control group 
(factor A) taking into account the sex (factor B) and the age (covariate). Significance was set at P ≤ 0.05. Med-
calc software, Ostend, Belgium. 
3. Results 
The Levene’s test was not significant assuming the equality of variances. A significant linear relation existed 
between the plasma sclerostin values and the age (R2 = 0.12; P = 0.03). Figure 3 illustrates the results of the li-
near regression calculation for the two groups: the OC-affected horses and the control group. A significant linear 
relationship was observed only in the control group (R2 = 0.28; P = 0.01).  
The global linear model showed a significant effect of the OC-status (P = 0.035) and a non-significant effect 
of the sex (P = 0.75). Mean values of sclerostin (±SE) in the OC-affected horses were 71.6 ± 3.3 pmole/L and 
61.5 +/− 3.2 pmole/l in the control horses. Figure 4 illustrates the box and wisker plot. 
4. Discussion 
To our knowledge, this is the first time that the circulating levels of sclerostin are measured in horses. A recent 
study shows that sclerostin in humans varies according to sex and age [16] and that sclerostin levels were higher 
in men than in women independently of their age. This was explained by the higher bone mass that men usually 
have. Sclerostin is mainly expressed by osteocytes, so individuals with higher bone mass, consequently, have a  
 
 
Figure 3. Linear relationship between of sclerostin levels in the 
OC (blue) and in the control group (red) related to the age. Both 
groups together show a significant (P = 0.03) decrease in the 
sclerostin concentration with age. When considered separately, 
the linear relation is only significant in the healthy group (P = 
0.01).                                                 




Figure 4. Box and Wisker plot comparing the OC and the control group. The 
OC affected group has a significant (P = 0.035) higher concentration of 
sclerostin than the control group.                                      
 
higher number of osteocytes. Sclerostin levels in humans are rising with age, but studies concerned people aged 
from 20 to approximately 60 years. In our study we found that sclerostin levels are decreasing with the age but 
our study included only young horses during their growth. The adult human normal values of sclerostin in serum 
were between 10 and 40 pmole/L [16]. Until now, there were no reference values in horses. Our control group 
(not affected by osteochondrosis) had a mean value of 61.5 pmole/L. The affected group had a mean value of 
71.6 pmole/L in serum. For this reason, we have chosen to perform a case control study and two groups of 
young horses of the same age were selected. The horses of the control group did not show any signs of OC in the 
fetlocks, hocks and stifles. For the OC-affected horses we have chosen only cases with radiological lesions as-
sociated that were undoubtedly osteochondrosis in the hocks or the stifles. Indeed, some lesions in the fetlocks 
are not clearly associated with osteochondrosis such as the first phalanx dorsal or plantar fragments [17]. Fur-
thermore, all the horses were weaned and examined during the winter period in order to minimize the environ-
mental effects A study performed in 2014 shows that sclerostin levels are influenced by season in human [18]. 
In winter season, sclerostin concentration is 20% higher than the all-year mean. 
Several limitations of our study came from the fact that we did not know the exact composition of the diet, the 
housing conditions, the body condition scores and intensity of daily exercise. All these factors may influence the 
expression of the disease [19]-[21]. 
Based on a digital gene expression analysis, our group analyzed the transcript profile of leukocytes from 
horses affected with OC using the high throughput sequencing method digital gene expression analysis [6]. Me-
tabolic pathway analysis showed an obvious dysregulation of several signaling pathways related to cartilage 
formation and cartilage repair such as Wnt/β-catenin, Indian hedgehog- and TGF-β signaling pathways. Other 
genes regulated may play a role in high carbohydrate diet, abnormal insulin metabolism or inflammation [6]. 
Furthermore, the transcript profile of leukocytes demonstrated that OC-related genes are differentially expressed 
in horses of different ages when compared to their age-matched controls and are differently expressed according 
the affect joints in young foals (<12 months) [22] [23]. Recently a miRNAs profile study in cartilage samples 
showed that miRNAs might be involved in equine OC physiopathology and in the cellular response to the bio-
mechanical stress in cartilage and bone [24]. 
Wnt/β-catenin signaling pathway is a major regulator of the bone activity [25]. The activation of this pathway 
leads to the formation and differentiation of osteoblastic cells, which create and increase the bone mass. This 
pathway starts when the appropriate Wnt peptide binds to the receptors LRP4, 5 and 6 (lipoprotein receptor re-
lated-protein) [26]. Sclerostin is an antagonist peptide of Wnt/β-catenin pathway that binds to these receptors 
acting as a negative regulator of the bone formation. 
Concerning the possible implication of Wnt/β-catenin pathway in the osteochondrosis, Power and others [7] 
demonstrated that sclerostin was increased in naturally occurring lesions of growth cartilage. They concluded 
D. Serteyn et al. 
 
 6 
that given that sclerostin protein is increased in lesions of OC, and that OC is associated with retained cartilage, 
it is possible that sclerostin may be having an effect on the cartilage via protease action, as proposed in OA. In 
that study samples were taken from stifle cartilage. In our study, the sclerostin concentrations were measured in 
peripheral blood. 
Besides the effects on bone metabolism and the growing awareness of the role of sclerostin in human osteo-
porosis, the Wnt/β-catenin pathway and sclerostin are also involved in certain inflammatory and metabolic dis-
eases such as obesity and diabetes [27] [28]. For example, humans suffering from type 2 diabetes have higher 
sclerostin levels that the controls [27]. 
Several omics studies underlined also the role of an energetic metabolism dysfunction in the osteochondrosis 
development. Desjardin and others [29] observed abnormal mitochondria and endoplasmic reticulum in the deep 
zone of OC cartilage. The mitochondrial dysfunction could be partially explained by the altered Wnt/β-catenin 
signaling pathway also known as a key regulator of mitochondrial function [6] [7] [30]. 
Sclerostin is expressed by the SOST gene and a modulation of sclerostin levels appears to be a finely tuned 
mechanism by which osteoblast, chondrocytes and progenitor cells coordinate regional and local osteogenesis 
[31]. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in 
postmenopausal women [32]. Delgado-Calle and others [33] showed that the SOST is subject to an epigenetic 
regulation. In that study osteoblasts were hypermethylated and osteocytes were hypomethylated in a CpG-rich 
region in the SOST proximal promoter.  
5. Conclusion 
To conclude, based on the recent studies in equine and human medicine, we can support the concept that genetic 
and epigenetic changes in SOST gene influence its bone mRNA expression and serum sclerostin levels in os-
teochondrosis. These results reinforce the possible role of the Wnt/β-catenin signaling pathway in the OC pa-
thogeny. However, as in human medicine, more studies are needed to define an eventual clinic interest of plas-
ma sclerostin as future biomarker in bone and cartilage diseases. 
Acknowledgements 
We thank the Wallonia Region for their funding providing. We also thank B. Deliege, A. Niesten and P. Lejeune 
for their excellent technical assistance. 
References 
[1] Rejno, S. and Stromberg, B. (1978) Osteochondrosis in the Horse. II. Pathology. Acta Radiologica-Supplement, 358, 
153-178. 
[2] Ytrehus, B., Carlson, C.S. and Ekman, S. (2007) Etiology and Pathogenesis of Osteochondrosis. Veterinary Pathology, 
44, 429-448. http://dx.doi.org/10.1354/vp.44-4-429 
[3] Verwilghen, D.R., Janssens, S., Busoni, V., Pille, F., Johnston, C. and Serteyn, D. (2013) Do Developmental Ortho-
paedic Disorders Influence Future Jumping Performances in Warmblood Stallions? Equine Veterinary Journal, 45, 
578-581. http://dx.doi.org/10.1111/evj.12027 
[4] McIlwraith, C.W. (1993) Inferences from Referred Clinical Cases of Osteochondritis Dissecans. Equine Veterinary 
Journal, 25, 27-30. http://dx.doi.org/10.1111/j.2042-3306.1993.tb04850.x 
[5] Jeffcott, L.B. (1991) Osteochondrosis in the Horse-Searching for the Key to Pathogenesis. Equine Veterinary Journal, 
23, 331-338. http://dx.doi.org/10.1111/j.2042-3306.1991.tb03733.x 
[6] Serteyn, D., Piquemal, D., Vanderheyden, L., Lejeune, J.P., Verwilghen, D. and Sandersen, C. (2010) Gene Expression 
Profiling from Leukocytes of Horses Affected by Osteochondrosis. Journal of Orthopaedic Research, 28, 965-970. 
[7] Power, J., Hernandez, P., Wardale, J. and Henson, F.M.D. (2014) Alterations in Sclerostin Protein in Lesions of Equine 
Osteochondrosis. Veterinary Record Open, 1, e000005-e000005. http://dx.doi.org/10.1136/vropen-2013-000005 
[8] ten Dijke, P., Krause, C., de Gorter, D.J., Lowik, C.W. and van Bezooijen, R.L. (2008) Osteocyte-Derived Sclerostin 
Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt Signaling. Journal of Bone and Joint Sur-
gery, 90(S1), 31-35. http://dx.doi.org/10.2106/JBJS.G.01183 
[9] Moester, M.J., Papapoulos, S.E., Lowik, C.W. and van Bezooijen, R.L. (2010) Sclerostin: Current Knowledge and Fu-
ture Perspectives. Calcified Tissue International, 87, 99-107. http://dx.doi.org/10.1007/s00223-010-9372-1 
D. Serteyn et al. 
 
 7 
[10] Chan, B.Y., Fuller, E.S., Russell, A.K., Smith, S.M., Smith, M.M., Jackson, M.T., Cake, M.A., Read, R.A., Bateman, 
J.F., Sambrook, P.N. and Little, C.B. (2011) Increased Chondrocyte Sclerostin May Protect against Cartilage Degrada-
tion in Osteoarthritis. Osteoarthritis and Cartilage, 19, 874-885. http://dx.doi.org/10.1016/j.joca.2011.04.014 
[11] Gaudio, A., Privitera, F., Battaglia, K., Torrisi, V., Sidoti, M.H., Pulvirenti, I., Canzonieri, E., Tringali, G. and Fiore, 
C.E. (2012) Sclerostin Levels Associated with Inhibition of the Wnt/Beta-Catenin Signaling and Reduced Bone Turn-
over in Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology & Metabolism, 97, 3744-3750.  
http://dx.doi.org/10.1210/jc.2012-1901 
[12] Appelman-Dijkstra, N.M. and Papapoulos, S.E. (2014) Novel Approaches to the Treatment of Osteoporosis. Best 
Practice & Research Clinical Endocrinology & Metabolism, 28, 843-857. 
http://dx.doi.org/10.1016/j.beem.2014.07.003 
[13] Zhang, H., He, J.W., Wang, C., Zhang, Z., Yue, H., Hu, W.W., Gu, J.M., Hu, Y.Q., Li, M., Fu, W.Z. and Zhang, Z.L. 
(2014) Associations of Polymorphisms in the SOST Gene and Bone Mineral Density in Postmenopausal Chinese 
Women. Osteoporosis International, 25, 2797-2803. http://dx.doi.org/10.1007/s00198-014-2832-0 
[14] Brabnikova-Maresova, K., Jarosova, K., Pavelka, K. and Stepan, J.J. (2014) Serum Sclerostin in Adult High-Activity 
Patients with Juvenile Idiopathic Arthritis. Arthritis Research & Therapy, 16, 460. 
http://dx.doi.org/10.1186/s13075-014-0460-x 
[15] Denoix, J.M., Jacquet, S., Lepeule, J., Crevier-Denoix, N., Valette, J.P. and Robert, C. (2013) Radiographic Findings 
of Juvenile Osteochondral Conditions Detected in 392 Foals Using a Field Radiographic Protocol. The Veterinary 
Journal, 197, 44-51. http://dx.doi.org/10.1016/j.tvjl.2013.03.040 
[16] Modder, U.I., Hoey, K.A., Amin, S., McCready, L.K., Achenbach, S.J., Riggs, B.L., Melton 3rd, L.J. and Khosla, S. 
(2011) Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men. Journal of Bone 
and Mineral Research, 26, 373-379. http://dx.doi.org/10.1002/jbmr.217 
[17] Hilla, D. and Distl, O. (2014) Heritabilities and Genetic Correlations between Fetlock, Hock and Stifle Osteochondro-
sis and Fetlock Osteochondral Fragments in Hanoverian Warmblood Horses. Journal of Animal Breeding and Genetics, 
131, 71-81. http://dx.doi.org/10.1111/jbg.12062 
[18] Dawson-Hughes, B., Harris, S.S., Ceglia, L. and Palermo, N.J. (2014) Serum Sclerostin Levels Vary with Season. 
Journal of Clinical Endocrinology & Metabolism, 99, E149-E152. http://dx.doi.org/10.1210/jc.2013-3148 
[19] Vander Heyden, L., Lejeune, J.P., Caudron, I., Detilleux, J., Sandersen, C., Chavatte, P., Paris, J., Deliege, B. and Ser-
teyn, D. (2013) Association of Breeding Conditions with Prevalence of Osteochondrosis in Foals. Veterinary Record, 
172, 68. http://dx.doi.org/10.1136/vr.101034 
[20] Robert, C., Valette, J.P., Jacquet, S., Lepeule, J. and Denoix, J.M. (2013) Study Design for the Investigation of Likely 
Aetiological Factors of Juvenile Osteochondral Conditions (JOCC) in Foals and Yearlings. The Veterinary Journal, 
197, 36-43. http://dx.doi.org/10.1016/j.tvjl.2013.03.039 
[21] Lepeule, J., Bareille, N., Robert, C., Valette, J.P., Jacquet, S., Blanchard, G., Denoix, J.M. and Seegers, H. (2013) As-
sociation of Growth, Feeding Practices and Exercise Conditions with the Severity of the Osteoarticular Status of Limbs 
in French Foals. The Veterinary Journal, 197, 65-71. http://dx.doi.org/10.1016/j.tvjl.2013.03.043 
[22] Serteyn, D., Piquemal, D., Mendoza, L., Caudron, I., Noguier, F., Bruno, R., Sandersen, C. and Lejeune, J.P. (2014) 
Osteochondrosis-Related Gene Expression in Equine Leukocytes Differs among Affected Joints in Foals. Journal of 
Molecular Biomarkers & Diagnosis, 5, 189. http://dx.doi.org/10.4172/2155-9929.1000189 
[23] Mendoza, L., Piquemal, D., Lejeune, J.P., Vander Heyden, L., Noguier, F., Bruno, R., Sandersen, C. and Serteyn, D. 
(2014) Age-Dependent Expression of Osteochondrosis-Related Genes in Equine Leukocytes. Veterinary Record, Un-
published. 
[24] Desjardin, C., Vaiman, A., Mata, X., Legendre, R., Laubier, J., Kennedy, S.P., Laloe, D., Barrey, E., Jacques, C., Cri-
biu, E.P. and Schibler, L. (2014) Next-Generation Sequencing Identifies Equine Cartilage and Subchondral Bone 
miRNAs and Suggests Their Involvement in Osteochondrosis Physiopathology. BMC Genomics, 15, 798. 
http://dx.doi.org/10.1186/1471-2164-15-798 
[25] Xu, H., Duan, J., Ning, D., Li, J., Liu, R., Yang, R., Jiang, J.X. and Shang, P. (2014) The Role of Wnt Signaling in 
Fracture Healing. BMB Reports. 
[26] Baron, R. and Rawadi, G. (2007) Targeting the Wnt/Beta-Catenin Pathway to Regulate Bone Formation in the Adult 
Skeleton. Endocrinology, 148, 2635-2643. http://dx.doi.org/10.1210/en.2007-0270 
[27] Garcia-Martin, A., Rozas-Moreno, P., Reyes-Garcia, R., Morales-Santana, S., Garcia-Fontana, B., Garcia-Salcedo, J.A. 
and Munoz-Torres, M. (2012) Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus. 
Journal of Clinical Endocrinology & Metabolism, 97, 234-241. http://dx.doi.org/10.1210/jc.2011-2186 
[28] Klangjareonchai, T. and Nimitphong, H. (2014) Circulating Sclerostin and Irisin Are Related and Interact with Gender 
to Influence Adiposity in Adults with Prediabetes. International Journal of Endocrinology, 2014, Article ID: 261545. 
D. Serteyn et al. 
 
 8 
[29] Desjardin, C., Chat, S., Gilles, M., Legendre, R., Riviere, J., Mata, X., Balliau, T., Esquerre, D., Cribiu, E.P., Betch, 
J.M. and Schibler, L. (2014) Involvement of Mitochondrial Dysfunction and ER-Stress in the Physiopathology of 
Equine Osteochondritis Dissecans (OCD). Experimental and Molecular Pathology, 96, 328-338. 
http://dx.doi.org/10.1016/j.yexmp.2014.03.004 
[30] Yoon, J.C., Ng, A., Kim, B.H., Bianco, A., Xavier, R.J. and Elledge, S.J. (2010) Wnt Signaling Regulates Mitochon-
drial Physiology and Insulin Sensitivity. Genes & Development, 24, 1507-1518. http://dx.doi.org/10.1101/gad.1924910 
[31] Robling, A.G., Niziolek, P.J., Baldridge, L.A., Condon, K.W., Allen, M.R., Alam, I., Mantila, S.M., Gluhak-Heinrich, 
J., Bellido, T.M., Harris, S.E. and Turner, C.H. (2008) Mechanical Stimulation of Bone in Vivo Reduces Osteocyte 
Expression of Sost/Sclerostin. The Journal of Biological Chemistry, 283, 5866-5875. 
 http://dx.doi.org/10.1074/jbc.M705092200 
[32] Reppe, S., Noer, A., Grimholt, R.M., Halldorsson, B.V., Medina-Gomez, C., Gautvik, V.T., Olstad, O.K., Berg, J.P., 
Datta, H., Estrada, K., Hofman, A., Uitterlinden, A.G., Rivadeneira, F., Lyle, R., Collas, P. and Gautvik, K.M. (2014) 
Methylation of Bone SOST, Its mRNA, and Serum Sclerostin Levels Correlate Strongly with Fracture Risk in Post-
menopausal Women. Journal of Bone and Mineral Research, Published Online. http://dx.doi.org/10.1002/jbmr.2342 
[33] Delgado-Calle, J., Arozamena, J., Perez-Lopez, J., Bolado-Carrancio, A., Sanudo, C., Agudo, G., de la Vega, R., 
Alonso, M.A., Rodriguez-Rey, J.C. and Riancho, J.A. (2013) Role of BMPs in the Regulation of Sclerostin as Re-
vealed by an Epigenetic Modifier of Human Bone Cells. Molecular and Cellular Endocrinology, 369, 27-34. 
http://dx.doi.org/10.1016/j.mce.2013.02.002 
